ATE406444T1 - Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung - Google Patents

Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung

Info

Publication number
ATE406444T1
ATE406444T1 AT04076254T AT04076254T ATE406444T1 AT E406444 T1 ATE406444 T1 AT E406444T1 AT 04076254 T AT04076254 T AT 04076254T AT 04076254 T AT04076254 T AT 04076254T AT E406444 T1 ATE406444 T1 AT E406444T1
Authority
AT
Austria
Prior art keywords
disease
proteins
directed
alzheime
detection
Prior art date
Application number
AT04076254T
Other languages
English (en)
Inventor
La Monte Suzanne M De
Jack R Wands
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE406444T1 publication Critical patent/ATE406444T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474Pancreatic thread protein; Reg protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
AT04076254T 1993-04-20 1994-04-20 Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung ATE406444T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5055993A 1993-04-20 1993-04-20

Publications (1)

Publication Number Publication Date
ATE406444T1 true ATE406444T1 (de) 2008-09-15

Family

ID=21965952

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94915396T ATE312348T1 (de) 1993-04-20 1994-04-20 Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung
AT04076254T ATE406444T1 (de) 1993-04-20 1994-04-20 Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94915396T ATE312348T1 (de) 1993-04-20 1994-04-20 Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung

Country Status (11)

Country Link
EP (2) EP1564293B9 (de)
JP (2) JP3513859B2 (de)
KR (1) KR100392244B1 (de)
AT (2) ATE312348T1 (de)
CA (1) CA2161097A1 (de)
DE (2) DE69435136D1 (de)
DK (2) DK0697893T3 (de)
ES (2) ES2255054T3 (de)
NZ (1) NZ266072A (de)
PT (1) PT1564293E (de)
WO (1) WO1994023756A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5936078A (en) * 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
WO1997021807A1 (fr) * 1995-12-12 1997-06-19 Kyowa Hakko Kogyo Co., Ltd. Nouveaux adn, nouveaux polypeptides et nouveaux anticorps
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
KR20000075748A (ko) * 1997-02-26 2000-12-26 마빈 씨. 구트리 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계
JP2001514663A (ja) 1997-03-12 2001-09-11 エスモンド,ロバート ダブリュー. アルツハイマー病を処置または予防するための方法
ATE381342T1 (de) * 2001-05-16 2008-01-15 Nymox Corp Prävention des zelltodes durch verwendung von segmenten der neurofilamentproteinen
EP1541166B1 (de) * 2001-05-16 2007-12-19 Nymox Corporation Prävention des Zelltodes durch Verwendung von Segmenten der Neurofilamentproteinen
US6770797B2 (en) * 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP1714979A3 (de) * 2001-11-16 2007-04-25 Nymox Corporation Peptide für die Behandlung von Tumoren und anderen Zuständen, die das entfernen oder zerstören von Zellen erfordern
CA2643100A1 (en) 2006-02-28 2007-09-07 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2023217890A1 (en) * 2022-05-10 2023-11-16 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting cfp-elk1 intergene region

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006332C (en) * 1988-12-21 2003-04-08 Suzanne De La Monte Method of detecting neurological disease or dysfunction

Also Published As

Publication number Publication date
DK0697893T3 (da) 2006-02-20
ES2312913T3 (es) 2009-03-01
JP3513859B2 (ja) 2004-03-31
KR100392244B1 (ko) 2003-11-28
AU674581B2 (en) 1997-01-02
WO1994023756A1 (en) 1994-10-27
ATE312348T1 (de) 2005-12-15
JP2004097227A (ja) 2004-04-02
DE69435136D1 (de) 2008-10-09
EP0697893B1 (de) 2005-12-07
EP1564293A1 (de) 2005-08-17
AU6666994A (en) 1994-11-08
ES2255054T3 (es) 2006-06-16
EP1564293B9 (de) 2009-08-19
EP0697893A4 (de) 1996-12-18
DE69434844D1 (de) 2006-10-19
JPH08509808A (ja) 1996-10-15
EP1564293B1 (de) 2008-08-27
DE69434844T2 (de) 2006-12-14
CA2161097A1 (en) 1994-10-27
PT1564293E (pt) 2008-12-02
EP0697893A1 (de) 1996-02-28
DK1564293T3 (da) 2009-01-12
NZ266072A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
DE69435136D1 (de) Geneexpression der Neurofilamentproteine und Nachweis der alzheimeschen Erkrankung
EP0442961A4 (en) Hybrid procoagulant proteins
PT939804E (pt) Neutroquina alfa
SE8106641L (sv) Hybrida humanleukocytinterferoner
DE69735375D1 (de) Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
ATE231551T1 (de) Huntingtin-dna, protein und verwendung
ATE73494T1 (de) Antigene proteine und diese enthaltende impfstoffe zur verhuetung von kokzidiose.
ATE301716T1 (de) Vmp-ähnliche sequenzen von pathogener borrelia
ATE365744T1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE69635207D1 (de) Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.
DK1015477T3 (da) 32 humane sekreterede proteiner
NO177863C (no) Fremgangsmåte for fremstilling av rekombinant humant IFN-type I, IFN1, IFN-pseudo-2, -3, og -4, samt ekspresjonsvektorer
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
ATE187202T1 (de) Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung
AU5315790A (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes
NO962596L (no) Nytt tumorsupressorgen
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
ZA200207883B (en) The High Bone Mass Gene of 11Q13.3.
DE69734890D1 (de) Rdgb-proteine
Schröder et al. Identification of a novel platelet-derived neutrophil-chemotactic polypeptide with structural homology to platelet-factor 4
ATE193324T1 (de) Rekombinante herstellung von laktoperoxidase
EP0839910A3 (de) Spo-rel, ein relA/spoT Homolog aus Staphylococcus
MX9801603A (es) Alteraciones geneticas relacionadas con la enfermedad de alzheimer hereditaria.
EA199900339A1 (ru) Ген роста человека и область гена, ответственная за низкий рост

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1564293

Country of ref document: EP

REN Ceased due to non-payment of the annual fee